Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in CKD: translational opportunities and challenges
暂无分享,去创建一个
G. Remuzzi | G. Tedeschi | D. Rastenytė | G. Spasovski | A. Więcek | G. Martino | D. Viggiano | A. Beck‐Sickinger | M. Okusa | F. Mallamaci | A. Bruchfeld | Carmine Zoccali | A. Ortíz | M. Rroji | J. Małyszko | Sol Carriazo | B. Spoto | I. Rychlík | C. Mayer | Andreja Figurek | Justina Kurganaite | Inga Arune Blumbyte | Sarina Rudolf | Vaiva | Sarkeviciene | Mustapha Arici | M. Arici
[1] P. Timpson,et al. Peripheral-specific Y1 receptor antagonism increases thermogenesis and protects against diet-induced obesity , 2021, Nature Communications.
[2] Wei Huang,et al. Neuropeptide Y mediates cardiac hypertrophy through microRNA-216b/FoxO4 signaling pathway , 2021, International journal of medical sciences.
[3] A. Garg,et al. Biomarkers of inflammation and repair in kidney disease progression. , 2020, The Journal of clinical investigation.
[4] G. Mancia,et al. Sympathetic nerve traffic overactivity in chronic kidney disease: a systematic review and meta-analysis , 2020, Journal of hypertension.
[5] Ying-ying Zhou,et al. Neuropeptide Y Is an Immunomodulatory Factor: Direct and Indirect , 2020, Frontiers in Immunology.
[6] E. Sabban,et al. Sex Differences in the Neuropeptide Y System and Implications for Stress Related Disorders , 2020, Biomolecules.
[7] W. Ju,et al. A role for NPY-NPY2R signaling in albuminuric kidney disease , 2020, Proceedings of the National Academy of Sciences.
[8] G. Capasso,et al. Mechanisms of cognitive dysfunction in CKD , 2020, Nature Reviews Nephrology.
[9] D. Iosifescu,et al. Neuropeptide Y in PTSD, MDD, and chronic stress: A systematic review and meta‐analysis , 2020, Journal of neuroscience research.
[10] Ian J Deary,et al. Reliability and validity of the UK Biobank cognitive tests , 2019, PloS one.
[11] P. Shende,et al. Physiological and Therapeutic Roles of Neuropeptide Y on Biological Functions. , 2019, Advances in experimental medicine and biology.
[12] E. Badr,et al. Relation of neuropeptide Y gene expression and genotyping with hypertension in chronic kidney disease , 2019, Biochemistry and biophysics reports.
[13] Xi Ma,et al. The role of neuropeptide Y and peptide YY in the development of obesity via gut-brain axis. , 2019, Current protein & peptide science.
[14] J. Kopp,et al. Renal Failure Patients in Disasters , 2019, Disaster Medicine and Public Health Preparedness.
[15] C. Zoccali,et al. Neuropeptide Y predicts cardiovascular events in chronic kidney disease patients: a cohort study. , 2019, Journal of hypertension.
[16] M. Bots,et al. Neuropeptide Y and chronic kidney disease progression: a cohort study. , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[17] P. Leeson,et al. The Role of Neuropeptide Y in Cardiovascular Health and Disease , 2018, Front. Physiol..
[18] N. Brown,et al. DPP (Dipeptidyl Peptidase)-4 Inhibition Potentiates the Vasoconstrictor Response to NPY (Neuropeptide Y) in Humans During Renin-Angiotensin-Aldosterone System Inhibition , 2018, Hypertension.
[19] D. Llewellyn,et al. Which Risk Factors Causally Influence Dementia? A Systematic Review of Mendelian Randomization Studies , 2018, Journal of Alzheimer's disease : JAD.
[20] S. Southwick,et al. A Randomized Dose-Ranging Study of Neuropeptide Y in Patients with Posttraumatic Stress Disorder , 2017, The international journal of neuropsychopharmacology.
[21] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[22] Zhiye Wu,et al. A Promising Therapeutic Target for Metabolic Diseases: Neuropeptide Y Receptors in Humans , 2017, Cellular Physiology and Biochemistry.
[23] J. Kornhuber,et al. Neuropeptide Y prolongs non-social memory and differentially affects acquisition, consolidation, and retrieval of non-social and social memory in male mice , 2017, Scientific Reports.
[24] J. González,et al. Novel genes involved in severe early-onset obesity revealed by rare copy number and sequence variants , 2017, PLoS genetics.
[25] C. Cavadas,et al. Neuropeptide Y (NPY) as a therapeutic target for neurodegenerative diseases , 2016, Neurobiology of Disease.
[26] D. D. de Luis,et al. Association of Neuropeptide Y Gene rs16147 Polymorphism with Cardiovascular Risk Factors, Adipokines, and Metabolic Syndrome in Patients with Obesity , 2016, Lifestyle Genomics.
[27] Ching-Chu Chen,et al. Sitagliptin and risk of heart failure hospitalization in patients with type 2 diabetes on dialysis: A population-based cohort study , 2016, Scientific Reports.
[28] R. Matyal,et al. Neuropeptide Y is an angiogenic factor in cardiovascular regeneration. , 2016, European journal of pharmacology.
[29] D. Woldbye,et al. The role of NPY in learning and memory , 2016, Neuropeptides.
[30] J. Ai,et al. Long-Term Administration of Neuropeptide Y in the Subcutaneous Infusion Results in Cardiac Dysfunction and Hypertrophy in Rats , 2015, Cellular Physiology and Biochemistry.
[31] M. Böhm,et al. Neuropeptide Y as an indicator of successful alterations in sympathetic nervous activity after renal sympathetic denervation , 2015, Clinical Research in Cardiology.
[32] G. Ferns,et al. Association of neuropeptide Y gene rs16147 polymorphism with metabolic syndrome in patients with documented coronary artery disease , 2015, Annals of human biology.
[33] F. Reichmann,et al. The homeostatic role of neuropeptide Y in immune function and its impact on mood and behaviour , 2015, Acta physiologica.
[34] C. Beste,et al. NPY2-receptor variation modulates iconic memory processes , 2014, European Neuropsychopharmacology.
[35] G. Pasterkamp,et al. Vascular neuropeptide Y contributes to atherosclerotic plaque progression and perivascular mast cell activation. , 2014, Atherosclerosis.
[36] Wei Zhang,et al. Hypothalamus-adipose tissue crosstalk: neuropeptide Y and the regulation of energy metabolism , 2014, Nutrition & Metabolism.
[37] Bo Zhao,et al. Neuropeptide Y Gene Promoter -399T/C Polymorphism Increases Risk of Ischemic Stroke. , 2013, Balkan medical journal.
[38] A. Beck‐Sickinger,et al. Neuropeptide Y receptors: how to get subtype selectivity , 2013, Front. Endocrin..
[39] T. Bek,et al. Neurogenic contractions in intraocular porcine ciliary arteries are mediated by α₂-adrenoceptors and NPY₁ receptors and are inhibited by prostaglandin E₂ acting on prejunctional EP₄ receptors. , 2013, Experimental eye research.
[40] F. Reichmann,et al. Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut–brain axis , 2012, Neuropeptides.
[41] C. Nievergelt,et al. Neuropeptide Y (NPY): genetic variation in the human promoter alters glucocorticoid signaling, yielding increased NPY secretion and stress responses. , 2012, Journal of the American College of Cardiology.
[42] Z. Żukowska,et al. NPY and Stress 30 Years Later: The Peripheral View , 2012, Cellular and Molecular Neurobiology.
[43] G. Mancia,et al. Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney disease. , 2011, Clinical journal of the American Society of Nephrology : CJASN.
[44] Lei Zhang,et al. Peripheral‐Specific Y2 Receptor Knockdown Protects Mice From High‐Fat Diet‐Induced Obesity , 2011, Obesity.
[45] J. Slaets,et al. Association of cognitive function with albuminuria and eGFR in the general population. , 2011, Clinical journal of the American Society of Nephrology : CJASN.
[46] F. Locatelli,et al. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[47] Claes Wahlestedt,et al. Therapeutic potential of neuropeptide Y (NPY) receptor ligands , 2010, EMBO molecular medicine.
[48] Jeffrey N. Weiser,et al. Recognition of Peptidoglycan from the Microbiota by Nod1 Enhances Systemic Innate Immunity , 2010, Nature Medicine.
[49] S. Brenner,et al. Neuropeptide Y-family peptides and receptors in the elephant shark, Callorhinchus milii confirm gene duplications before the gnathostome radiation. , 2009, Genomics.
[50] W. Kraus,et al. Neuropeptide Y Gene Polymorphisms Confer Risk of Early-Onset Atherosclerosis , 2009, PLoS genetics.
[51] L. Bouter,et al. Neuropeptide Y polymorphism significantly magnifies diabetes and cardiovascular disease risk in obesity: the Hoorn Study , 2009, European Journal of Clinical Nutrition.
[52] Guang Yi Bai,et al. Different Regulation of Atrial ANP Release through Neuropeptide Y2 and Y4 Receptors , 2008, Journal of Korean medical science.
[53] T. Lehtimäki,et al. Neuropeptide Y signal peptide Pro7 substitution protects against coronary artery atherosclerosis: the Helsinki Sudden Death Study. , 2008, Atherosclerosis.
[54] Ahmad R. Hariri,et al. Genetic variation in human NPY expression affects stress response and emotion , 2008, Nature.
[55] A. Kribben,et al. Posttraumatic stress disorder in hemodialysis patients. , 2007, American Journal of Kidney Diseases.
[56] Y. Kesäniemi,et al. Leu7Pro polymorphism of PreproNPY associated with an increased risk for type II diabetes in middle-aged subjects , 2007, European Journal of Clinical Nutrition.
[57] S. Bloom,et al. Gut hormones and the regulation of energy homeostasis , 2006, Nature.
[58] M. Koulu,et al. The Leu7Pro polymorphism of neuropeptide Y is associated with younger age of onset of type 2 diabetes mellitus and increased risk for nephropathy in subjects with diabetic retinopathy. , 2006, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[59] J. Hinson. Neuropeptide Y and the Regulation of Endocrine Function , 2006 .
[60] W. Liang,et al. Neuropeptide Y induces cardiomyocyte hypertrophy via calcineurin signaling in rats , 2005, Regulatory Peptides.
[61] C. Zoccali. Neuropeptide Y as a far-reaching neuromediator: from energy balance and cardiovascular regulation to central integration of weight and bone mass control mechanisms. Implications for human diseases , 2005, Current opinion in nephrology and hypertension.
[62] W. März,et al. Association analysis of the polymorphism T1128C in the signal peptide of neuropeptide Y in a Swedish hypertensive population. , 2004, Journal of hypertension.
[63] D. Larhammar,et al. Molecular evolution of NPY receptor subtypes , 2004, Neuropeptides.
[64] H. Herzog,et al. NPY and Y receptors: lessons from transgenic and knockout models , 2004, Neuropeptides.
[65] C. Zoccali,et al. Prospective study of neuropeptide y as an adverse cardiovascular risk factor in end-stage renal disease. , 2003, Journal of the American Society of Nephrology : JASN.
[66] C. Zoccali,et al. Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease , 2003, Journal of hypertension.
[67] M. Koulu,et al. Changes in diurnal sympathoadrenal balance and pituitary hormone secretion in subjects with Leu7Pro polymorphism in the prepro-neuropeptide Y. , 2003, The Journal of clinical endocrinology and metabolism.
[68] Lijun Li,et al. Neuropeptide Y–Induced Acceleration of Postangioplasty Occlusion of Rat Carotid Artery , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[69] S. Ebrahim,et al. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? , 2003, International journal of epidemiology.
[70] S. Southwick,et al. A functional neuropeptide Y Leu7Pro polymorphism associated with alcohol dependence in a large population sample from the United States. , 2002, Archives of general psychiatry.
[71] C. Zoccali,et al. Norepinephrine and Concentric Hypertrophy in Patients With End-Stage Renal Disease , 2002, Hypertension.
[72] K. Schlüter,et al. Neuropeptide Y modifies the hypertrophic response of adult ventricular cardiomyocytes to norepinephrine. , 2002, Cardiovascular research.
[73] M. Koulu,et al. Leucine7 to proline7 polymorphism in the preproneuropeptide Y is associated with the progression of carotid atherosclerosis, blood pressure and serum lipids in Finnish men. , 2001, Atherosclerosis.
[74] M. Koulu,et al. Altered intracellular processing and release of neuropeptide Y due to leucine 7 to proline 7 polymorphism in the signal peptide of preproneuropeptide Y in humans1 , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[75] D. Larhammar,et al. Origins of the many NPY-family receptors in mammals , 2001, Peptides.
[76] L. Edvinsson,et al. Neuropeptide Y—Mediated Constriction and Dilation in Rat Middle Cerebral Arteries , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[77] A. Beck‐Sickinger,et al. The First Selective Agonist for the Neuropeptide YY5Receptor Increases Food Intake in Rats* , 2000, The Journal of Biological Chemistry.
[78] L. Niskanen,et al. Leucine 7 to proline 7 polymorphism in the neuropeptide Y gene is associated with enhanced carotid atherosclerosis in elderly patients with type 2 diabetes and control subjects. , 2000, The Journal of clinical endocrinology and metabolism.
[79] C. A. Morgan,et al. Plasma neuropeptide-Y concentrations in humans exposed to military survival training , 2000, Biological Psychiatry.
[80] L. Niskanen,et al. Leucine 7 to proline 7 polymorphism in the neuropeptide y gene is associated with retinopathy in type 2 diabetes. , 2000, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[81] P. Blankestijn,et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. , 1999, The New England journal of medicine.
[82] G. Remuzzi. Sympathetic overactivity in hypertensive patients with chronic renal disease. , 1999, The New England journal of medicine.
[83] L. Minthon,et al. Somatostatin and neuropeptide Y in cerebrospinal fluid: correlations with severity of disease and clinical signs in Alzheimer's disease and frontotemporal dementia. , 1997, Dementia and Geriatric Cognitive Disorders.
[84] K. Fuxe,et al. Localization of Neuropeptide Y Y1 mRNA in the Human Brain: Abundant Expression in Cerebral Cortex and Striatum , 1997, The European journal of neuroscience.
[85] I. Meredith,et al. Region-specific neuropeptide Y overflows at rest and during sympathetic activation in humans. , 1997, Hypertension.
[86] D. M. Eadie,et al. Characterization of the human type 2 neuropeptide Y receptor gene (NPY2R) and localization to the chromosome 4q region containing the type 1 neuropeptide Y receptor gene. , 1996, Genomics.
[87] Yun Feng,et al. Molecular Characterization of a Second Mouse Pancreatic Polypeptide Receptor and Its Inactivated Human Homologue* , 1996, The Journal of Biological Chemistry.
[88] C. Strader,et al. Cloning and Expression of a Novel Neuropeptide Y Receptor* , 1996, The Journal of Biological Chemistry.
[89] S. Whitebread,et al. A receptor subtype involved in neuropeptide-Y-induced food intake , 1996, Nature.
[90] Yun Feng,et al. Cloning and characterization of a novel receptor to pancreatic polypeptide, a member of the neuropeptide Y receptor family , 1996, FEBS letters.
[91] D. Larhammar,et al. Cloning of a Human Receptor of the NPY Receptor Family with High Affinity for Pancreatic Polypeptide and Peptide YY (*) , 1995, The Journal of Biological Chemistry.
[92] T. Geiser,et al. Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes. , 1994, The Journal of biological chemistry.
[93] P. Widdowson,et al. Quantitative receptor autoradiography demonstrates a differential distribution of neuropeptide-Y Y1 and Y2 receptor subtypes in human and rat brain , 1993, Brain Research.
[94] H. Herzog,et al. Genomic organization, localization, and allelic differences in the gene for the human neuropeptide Y Y1 receptor. , 1993, The Journal of biological chemistry.
[95] T. Westfall,et al. In Vitro Effects of Neuropeptide Y at the Vascular Neuroeffector Junction a , 1990, Annals of the New York Academy of Sciences.
[96] L. Minthon,et al. Neuropeptide levels in Alzheimer's disease and dementia with frontotemporal degeneration. , 1990, Journal of neural transmission. Supplementum.
[97] James F. Flood,et al. Modulation of memory processing by neuropeptide Y , 1987, Brain Research.
[98] J. Morley,et al. Neuropeptide Y: anatomical distribution and possible function in mammalian nervous system. , 1986, Life sciences.
[99] T. Schwartz,et al. Pancreatic polypeptide: a hormone under vagal control. , 1983, Gastroenterology.